




RealRate

# PHARMACEUTICAL 2022

International Stem Cell CORP  
Rank 379 of 466



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 108% points. The greatest weakness of International Stem Cell CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 167% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 105% points below the market average of 78%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 2,334             |
| Cost of Goods Sold                          | 2,935             |
| Intangible Assets                           | 949               |
| Liabilities, Current                        | 4,284             |
| Liabilities, Non-Current                    | 950               |
| Other Assets                                | 1,279             |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 1,383             |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 1,022             |
| Other Revenues                              | 7,176             |
| Property and Equipment                      | 384               |
| Research and Development                    | 695               |
| Selling, General and Administrative Expense | 4,084             |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 4,946             |
| Liabilities              | 5,234             |
| Expenses                 | 9,097             |
| Revenues                 | 7,176             |
| Stockholders Equity      | -288              |
| Net Income               | -899              |
| Comprehensive Net Income | -899              |
| Economic Capital Ratio   | -27%              |